表紙
市場調查報告書

全球醫藥品銷售業務受託市場預測 (2019年∼2029年):詳細說明,非個人的推銷,醫療教育服務,樣品管理服務,遠程服務,電子醫藥行銷服務

Global Pharma Contract Sales Market 2019-2029: Contract Detailing/Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services, Cardiovascular Disease, Metabolic Disorders, Oncology

出版商 Visiongain Ltd 商品編碼 534094
出版日期 內容資訊 英文 253 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球醫藥品銷售業務受託市場預測 (2019年∼2029年):詳細說明,非個人的推銷,醫療教育服務,樣品管理服務,遠程服務,電子醫藥行銷服務 Global Pharma Contract Sales Market 2019-2029: Contract Detailing/Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services, Cardiovascular Disease, Metabolic Disorders, Oncology
出版日期: 2019年02月28日內容資訊: 英文 253 Pages
簡介

本報告提供全球醫藥品銷售業務受託市場相關調查,市場概要和各治療領域,各地區趨勢,法律規章及商業性預測,及打入市場的主要企業的簡介等彙整資料。

第1章 調查概要

第2章 醫藥品銷售業務受託的簡介

  • 市場定義
  • 所謂醫藥品銷售業務受託機關 (CSO)
  • CSO提供的服務
  • 製藥公司採用的各種行銷流通管道
  • 製藥產業整體的外包趨勢的擴大
  • 醫藥品銷售業務受託的崛起
  • 詳細說明
  • 各種企業的營業力的大幅度切割
  • 企業只詳細說明不能依賴

第3章 全球醫藥品銷售業務受託市場

  • 市場成果
  • 全球醫藥品銷售業務受託市場預測
  • 醫藥品銷售的外包的優點
  • 醫藥品銷售的外包的缺點
  • 主要的治療次市場
  • 醫藥品銷售業務受託的增加
  • 今後的變動
  • 心血管治療藥
  • 代謝性疾病治療藥
  • 癌症治療藥

第4章 主要服務部門

  • 主要的服務
  • 詳細說明
  • 非個人的推銷
  • 醫療教育服務
  • 樣品管理服務

第5章 法律規章及商業性預測

  • 目前主要國家市場
  • 市場預測
  • 各地區趨勢
  • 法律規章趨勢
  • 美國
  • EU5個國家
  • 日本

第6章 主要新興市場

  • 主要的新興市場
  • 金磚四國
  • 中國
  • 印度
  • 巴西
  • 俄羅斯

第7章 產業及市場趨勢

  • 優勢和弱點
  • 機會及威脅
  • STEP分析
  • 技術發展
  • 經濟壓力
  • 政治問題
  • 市場趨勢
  • 藥物開發趨勢的影響
  • 銷售模式的變革
  • 市場進入
  • 摘要

第8章 主要CSO

  • 目前產業趨勢
  • IQVIA HOLDINGS INC.
  • UDG Healthcare
  • QuintilesIMS
  • inVentiv Health
  • Publicis Healthcare Communications Group
  • OnCall, LLC
  • Marvecs
  • Sofip
  • CMIC

第9章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0357

The global pharma contract sales market is expected to grow at a CAGR of 8.9% in the first half of the forecast period. In 2018, the contract detailing segment held 76% of the global pharma contract sales market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 253-page report you will receive 104 tables and 67 figures- all unavailable elsewhere.

The 253-page report provides clear detailed insight into the global pharma contract sales market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Pharma Contract Sales Market forecasts from 2019-2029
  • Along with revenue prediction for the overall world market for pharma contract sales market, our investigation shows forecasts to 2029 for the following submarket by leading services:
  • Contract detailing (personal promotion/field sales)
  • Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and others
  • Medical education services
  • Sample management services
  • This report also breaks down the revenue forecast for pharma contract sales market by therapeutic segments:
  • Cardiovascular disease
  • Metabolic disorders
  • Oncology
  • Other
  • This report provides individual revenue forecasts to 2029 for these regional and national markets:
  • US
  • Japan
  • EU5: Germany, UK, France, Italy and Spain
  • BRIC: China, India, Brazil and Russia

The US, Japan, EU5 and BRIC markets are further segmented by therapeutic segments and leading services

image1

  • Our study discusses the SWOT and STEP factors of the global pharma contract sales market
  • Our study also discusses factors that will drive and restrain the global pharma contract sales market
  • Our study discusses issues affecting the pharma contract sales industry and market:
  • Outsourced and in-house sales reps - trends and emerging sales models, including multiple channels (multichannel marketing to medical professionals)
  • Services CSOs offer and benefits to drug companies outsourcing medical sales
  • Maturing brands and product launches, including flexibility in field sales teams
  • Legislation and new market access requirements for pharma sales representatives
  • Changes to online marketing and potential for IT technologies Risk-sharing agreements
  • Key account management (KAM) and medical science liaison (MSL)
  • This report discusses the leading companies in pharma contract sales:
  • CMIC
  • IQVIA
  • Marvecs
  • OnCall, LLC
  • Publicis Healthcare Communications Group (PHCG)
  • Sofip
  • Syneos Health (INC Research and inVentiv Health
  • UDG Healthcare

Visiongain's study is intended for anyone requiring commercial analyses for the global pharma contract sales market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Pharma Contract Sales Overview
  • 1.2 Why You Should Read This Report
  • 1.3 How this Report Delivers
  • 1.4 Main Questions Answered by this Report
  • 1.5 Who is this Report for?
  • 1.6 Research and Analysis Methods
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Reports
  • 1.9 About Visiongain

2. Introduction to Pharma Contract Sales Market

  • 2.1 Defining the Market
  • 2.2 What is a CSO?
  • 2.3 What Services do CSOs Provide?
  • 2.4 Marketing Channels Employed by Pharma Companies in 2018
  • 2.5 Growing Trend of Outsourcing in the Overall Pharma Industry
  • 2.6 Detailing: Becoming Less Relevant or is it as Important as Ever?
    • 2.6.1 Declining Access to Doctors: Trend Continues in 2018
  • 2.7 Large Cuts in Sales Force in Various Companies
  • 2.8 Companies Cannot Rely Solely Upon Detailing
    • 2.8.1 Trends Driving the Need for New Sales Models

3. Global Pharma Contract Sales Market 2019-2029

  • 3.1 The Market in 2018
  • 3.2 Global Pharma Contract Sales Market 2018-2024
    • 3.2.1 Growth in the Market in Recent Years
  • 3.3 Global Pharma Contract Sales Market 2018-2029
  • 3.4 The Factors that Will Drive Growth in this Market: Advantages of Outsourcing Pharma Sales
    • 3.4.1 Cost and Flexibility
    • 3.4.2 New Technologies and Sales Models
    • 3.4.3 Emerging Markets and Mature Brands
    • 3.4.4 Biosimilars
    • 3.4.5 Account Management, Medical Education and Patient Support Services
    • 3.4.6 Market Access Complexities Provide its Own Opportunities for CSOs
    • 3.4.7 New Drug Launches
    • 3.4.8 CDER's Novel Drug Approvals annually: 2014 - 2018
    • 3.4.9 Summary
  • 3.5 The Factors that Will Restrain Growth in this Market: Disadvantages of Outsourcing Pharma Sales
  • 3.6 Leading Therapeutic Submarkets for Pharma Contract Sales, Forecast 2018-2029
  • 3.7 The Rise in Pharma Contract Sales
  • 3.8 How Will the Therapeutic Composition of the Market Change Between 2018 and 2029?
  • 3.9 Contract Sales for Cardiovascular Drugs
    • 3.9.1 Current Status
    • 3.9.2 Recent Cardiovascular Drug Patent Expiries and FDA Approvals
    • 3.9.3 Cardiovascular and Cerebrovascular Conditions are the World's Most Fatal Diseases
    • 3.9.4 Contract Sales for Cardiovascular Drugs: Submarket Forecast 2018-2029
  • 3.10 Contract Sales for Metabolic Disorder Drugs
    • 3.10.1 Current Status
    • 3.10.2 430 Million People Expected to be Diagnosed with Diabetes by 2030
    • 3.10.3 Contract Sales for Metabolic Disorders: Submarket Forecast 2018-2029
  • 3.11 Contract Sales for Oncology Drugs
    • 3.11.1 Current Status
    • 3.11.2 Patent Expiries and Recent Approvals
    • 3.11.3 Contract Sales for Oncology Drugs Forecast 2018-2029

4. Leading Service Sectors of the Pharma Contract Sales Market 2018-2029

  • 4.1 The Leading Services
    • 4.1.1 Leading Service Sectors of the Market, Forecast 2018-2029
    • 4.1.2 How Will the Service Composition over the Market Change over the Next Ten Years?
  • 4.2 Contract Detailing Submarket
    • 4.2.1 Are we in the Midst of a Turnaround in Sales Rep Numbers in the Overall Pharma Industry?
    • 4.2.2 What are the Trends in Sales Reps Employed by CSOs?
    • 4.2.3 Detailing Services Offered by CSOs
    • 4.2.4 CSOs will be Impacted by Declining Physician Access as Much as In-House Reps
    • 4.2.5 Contract Detailing Submarket Forecast 2018-2029
    • 4.2.6 Drivers and Restraints for this Dominant Service Submarket
  • 4.3 Contract Non-Personal Promotion Submarket
    • 4.3.1 The Benefits for both Pharma Companies and Doctors
    • 4.3.2 Contract Non-Personal Promotion Submarket Forecast 2018-2029
    • 4.3.3 Drivers and Restraints for Contract Non-Personal Promotion: Multichannel Marketing in the 21st Century
    • 4.3.4 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Teledetailing and EDetailing
      • 4.3.4.1 Contract Teledetailing Submarket: Current Status
      • 4.3.4.2 Contract Teledetailing Submarket Forecast 2018-2029
      • 4.3.4.3 Drivers and Restraints for Outsourced Teledetailing
      • 4.3.4.4 Contract eDetailing Current Status
      • 4.3.4.5 Contract eDetailing Submarket Forecast 2018-2029
      • 4.3.4.6 Drivers and Restraints for Outsourced eDetailing
  • 4.4 Medical Education Services Submarket Current Status
    • 4.4.1 Medical Education Services Submarket Forecast 2018-2029
    • 4.4.2 Medical Education Services Drivers and Restraints
  • 4.5 Sample Management Services Submarket: Current Status
    • 4.5.1 Sample Management Services Submarket Forecast 2018-2029
    • 4.5.2 Drivers and Restraints for the Sample Management Services Submarket
    • 4.5.3 J. Knipper and Company Inc.: A US Leader in Sample Management Services
      • 4.5.3.1 Company Acquires Sample Management Divisions from Leading CSOs 2010-2014
      • 4.5.3.2 Construction Underway for New State of the Art Distribution Centre
      • 4.5.3.3 New Multi-Million Dollar Contact Centre Opened
      • 4.5.3.4 New Technologies to Drive Growth over the Next Ten Years

5. Leading National Markets for Pharma Contract Sales: Regulatory and Commercial Outlook 2018-2029

  • 5.1 Current Leading National Markets
  • 5.2 Leading Regional Markets Forecast 2018-2029
  • 5.3 How will the Regional Composition of the Market Change between now and 2028?
  • 5.4 Pharma Sales Regulatory Developments
    • 5.4.1 Physician Payment Legislation in the US, Europe and Japan
      • 5.4.1.1 The Physician Payment Sunshine Act (PPSA)
      • 5.4.1.2 Proposed Bill to Close a Large Loophole in the PPSA, Could Come into Effect in 2018
      • 5.4.1.3 Physician Payments in France: Increased Scrutiny
    • 5.4.2 Domestic and International Concerns over Bribery: Recent Legislation in the US and UK
      • 5.4.2.1 Promotional Products in the EU: New Rules
    • 5.4.3 New Market Access Requirements in EU5 Countries
      • 5.4.3.1 AMNOG: Stricter Pricing for Drugs in Germany
      • 5.4.3.2 AMNOG: Has Reduced Prices of Top Sellers by 23%
      • 5.4.3.3 Healthcare Reform in France: Pricing and Reimbursements have been set to Change for a While, is 2018 the Year It Finally Happens?
      • 5.4.3.4 PCTs Replaced by CCGs in the UK
      • 5.4.3.5 Pricing in the UK: Contentious Issue
    • 5.4.4 Overtime for Sales Reps in the US: Rule Clarifications
  • 5.5 US Pharma Contract Sales Market
    • 5.5.1 US Pharma Contract Sales Market Has Grown Rapidly
    • 5.5.2 Pharma Sales Regulation in the US
    • 5.5.3 US Pharma Contract Sales Market Forecast 2018-2029
  • 5.6 EU5 Pharma Contract Sales Market
    • 5.6.1 Regulating Pharma Sales in the EU
    • 5.6.2 Overall EU5 Pharma Contract Sales Market Forecast 2018-2029
    • 5.6.3 UK Pharma Contract Sales Market Forecast 2018-2029
    • 5.6.4 German Pharma Contract Sales Market Forecast 2018-2029
    • 5.6.5 French Pharma Contract Sales Market Forecast 2018-2029
    • 5.6.6 Italian Pharma Contract Sales Market Forecast 2018-2029
    • 5.6.7 Spanish Pharma Contract Sales Market Forecast 2018-2029
  • 5.7 Japanese Pharma Contract Sales Market
    • 5.7.1 Regulation
    • 5.7.2 Current Market Landscape
    • 5.7.3 Japanese Pharma Contract Sales Market Forecast 2018-2029

6. Leading Emerging Markets for Pharma Contract Sales: Regulatory and Commercial Outlook 2018-2029

  • 6.1 Pharma Contract Sales in Leading Emerging Markets in 2018
  • 6.2 BRIC Pharma Contract Sales Markets Forecast 2018-2029
  • 6.3 Chinese Pharma Contract Sales Market
    • 6.3.1 Current Pharma Contract Sales Landscape in China
    • 6.3.2 Rising In-House and Outsourced Sales Numbers
    • 6.3.3 Concerns over Bribery
    • 6.3.4 Chinese Pharma Contract Sales Market Forecast 2018-2029
  • 6.4 Indian Pharma Contract Sales Market
    • 6.4.1 Current Pharma Contract Landscape in India
    • 6.4.2 Government and Regulatory Guidelines for Interactions between Healthcare Professionals and Pharma Companies
    • 6.4.3 Indian Pharma Contract Sales Market Forecast 2018-2029
  • 6.5 Brazilian Pharma Contract Sales Market
    • 6.5.1 Current Pharma Contract Sales Landscape in Brazil
    • 6.5.2 State Payment Rules and Online Marketing Rules for Prescription Drugs
    • 6.5.3 Brazilian Pharma Contract Sales Market Forecast 2018-2029
  • 6.6 Russian Pharma Contract Sales Market
    • 6.6.1 Current Pharma Contract Sales Landscape in Russia
    • 6.6.2 New State Procurement Rules for Drugs Introduced in 2013
    • 6.6.3 Tougher Rules on Interactions between Doctors and Sales Reps in Russia
    • 6.6.4 Russian Pharma Contract Sales Market Forecast 2018-2029

7. Pharma Contract Sales: Industry and Market Trends 2018-2029

  • 7.1 Strengths and Weaknesses for the Global Pharma Contract Sales Market 2018-2029
  • 7.2 Opportunities and Threats for the Global Pharma Contract Sales Market 2018-2029
  • 7.3 Pharma Contract Sales Market: STEP Analysis 2018-2029
    • 7.3.1 Social Factors Affecting Pharma Contract Sales to 2028
    • 7.3.1.1 The Role of Ethics in Pharma Sales
  • 7.4 Technological Developments to Improve Sales Strategies
    • 7.4.1 Advantages of Using Tablets and Smartphones for Detailing
    • 7.4.1.1 CSOs Need to Maximise on the Benefits of New Technologies
    • 7.4.2 Closed Loop Marketing (CLM)
    • 7.4.3 Customer Relationship Management (CRM)
    • 7.4.4 The Advantages of Cloud Computing in Pharma Contract Sales
    • 7.4.5 Does Big Data Have a Role in Pharma Sales?
    • 7.4.6 Social Media in Relation to Pharma Sales
    • 7.4.6.1 FDA Releases Long-Awaited Guidance on the use of Social Media
    • 7.4.6.2 Pharma Industry is not Using Social Media to its Full Potential, but it offers many Benefits
  • 7.5 Economic Pressures are Limiting Healthcare and Marketing Budgets
  • 7.6 Political Issues: Stricter Regulations for Pharma Sales around the World
  • 7.7 Trends in Pharma Contract Sales 2018-2029
    • 7.7.1 Cuts to In-House Sales Staff Will Continue 2018-2029
    • 7.7.2 There will be in an Increase in Strategic Partnering in Order to Provide Long-Term Revenue Growth
    • 7.7.3 Leading CSOs have consolidated, and will continue to Consolidate, in Order to Increase Market Penetration
    • 7.7.4 CSOs and Pharma Clients Alike Need to Stay Vigilant about the Risks of Outsourcing Pharma Sales
  • 7.8 Drug Development Trends Affecting Pharma Sales 2018-2029
    • 7.8.1 How will Orphan Drug Diseases Influence Pharma Contract Sales?
    • 7.8.2 Promotion for Biosimilar Drugs over the Next Ten Years
    • 7.8.3 There will be Greater Demand for Specialty Medicines
    • 7.8.4 Emerging National Markets are Becoming Increasingly Important
  • 7.9 Sales Models Need to Evolve
    • 7.9.1 Why are Sales Reps Struggling for Access?
    • 7.9.1.1 One way to Fight Against Reduced Access is to Target the System as a Whole
    • 7.9.1.2 Multichannel Marketing to Overcome Problems of Access
    • 7.9.2 Key Account Management (KAM)
    • 7.9.3 Silos in Sales and Marketing
    • 7.9.4 The Use of KOLs in Pharma Sales
  • 7.10 Market Access
    • 7.10.1 Emerging Stakeholders in Pharma Sales
    • 7.10.2 The Rise of ACOs
    • 7.10.2.1 20% of US Hospitals were Part of an ACO in 2014
    • 7.10.3 Market Access in the EU Over the Next Ten Years
    • 7.10.4 CSOs and Market Access Consulting
  • 7.11 Summary: Main Trends Shaping Pharma Contract Sales 2018-2029

8. Leading Contract Sales Organisations (CSOs)

  • 8.1 Current Industry Landscape
  • 8.2 IQVIA HOLDINGS INC. (Quintiles & IMS)
    • 8.2.1 World Market Leader for Contract Sales and Market Access
    • 8.2.2 New Services and Strategic Partnerships
    • 8.2.3 IQVIA Integrated Health Services Segment Performance 2010-2015
    • 8.2.4 IQVIA Performance 2014-2018
    • 8.2.5 Outlook for QuintilesIMS Contract Sales to 2028
    • 8.2.6 QuintilesIMS Financial Performance Quarterly Review 2018
  • 8.3 UDG Healthcare
    • 8.3.1 Global Service Provider with Various Business Units
    • 8.3.2 Geographic and Service Growth Through Acquisitions
    • 8.3.3 Joint Venture with CMIC
    • 8.3.4 UDG Healthcare Financial Performance 2014-2018 and Beyond
  • 8.4 inVentiv Health (Syneos Health)
    • 8.4.1 Combined CRO and CCO
    • 8.4.2 Global Structure
    • 8.4.3 inVentiv Health Presence in US, EU and Asia
    • 8.4.4 Possible $500m IPO in the Near Future
    • 8.4.5 inVentiv Health Contract Sales Outlook to 2028
  • 8.5 Publicis Healthcare Communications Group
    • 8.5.1 PHCG Purchases PDI Commercial Services Business
      • 8.5.1.1 PDI Prior to Acquisition: Broad Service Portfolio, Resources which PHCG now Acquires
      • 8.5.1.2 PDI Past Financial Performance
    • 8.5.2 Publicis Touchpoint Solutions
      • 8.5.2.1 New Services in Recent Years, and Tardis Medical to be Aligned with the Company
  • 8.6 OnCall, LLC
    • 8.6.1 Range of Services
    • 8.6.2 Contracts with Promius Pharma
  • 8.7 Marvecs
    • 8.7.1 A Local Leader in Germany
    • 8.7.2 New Services Added in Recent Years: Sales 3.0
  • 8.8 Sofip
  • 8.9 CMIC
    • 8.9.1 CSO Business in Japan Since 2000
  • 8.10 Leading Players in China are not Just CSOs

9. Conclusions

  • 9.1 The Global Pharma Contract Sales Market in 2018
    • 9.1.1 Which Sectors Generated the Most Revenues in 2018?
    • 9.1.2 Spending on Contract Sales is Highest in the US and EU
  • 9.2 Outlook for the Pharma Contract Sales Market 2018-2029
    • 9.2.1 Growth Trends for the Leading Submarkets 2018-2029
    • 9.2.1.1 Therapeutic Sector Growth 2018-2029
  • 9.3 Commercial Drivers for Pharma Contract Sales

Appendices

  • Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 2.1 Recent Big Pharma Sales Force Cuts, Based Upon Reports and Predictions
  • Table 3.1 Global Pharma Contract Sales Market: Revenues ($bn), AGR (%), CAGR (%), 2018-2024
  • Table 3.2 Global Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
  • Table 3.3 Pharma Contract Sales Market Segmented by Therapeutic Area: Revenue ($bn), AGR (%), CAGR (%), 2018-2024
  • Table 3.4 Pharma Contract Sales Market Segmented by Therapeutic Area: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
  • Table 3.5 Leading Therapeutic Submarket Shares (%), 2019-2029
  • Table 3.6 Selected Recent Cardiovascular Disease Drug Patent Expiries, 2018
  • Table 3.7 Selected Cardiovascular Drugs Going Off-Patent 2018-2025
  • Table 3.8 Cardiovascular Drugs Approved by the FDA in 2016
  • Table 3.9 Cardiovascular Drugs Approved by the FDA in 2015
  • Table 3.10 Cardiovascular Drugs Approved by the FDA in 2014
  • Table 3.11 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), % of Total Deaths, Deaths Per 100,000 Population, 2015 and 2030
  • Table 3.12 Cardiovascular Disease Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2024
  • Table 3.13 Cardiovascular Disease Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
  • Table 3.14 Selected Metabolic Disorder Drugs Going Off-Patent 2016-2022
  • Table 3.15 Diabetes Prevalence in Leading National Markets, 2014
  • Table 3.16 Metabolic Disorders Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 3.17 Metabolic Disorders Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
  • Table 3.18 Selected Recent and Future Oncology Patent Expiries, 2016
  • Table 3.19 Oncology Drugs Approved by the FDA in 2015
  • Table 3.20 Oncology Drugs Approved by the FDA in 2016
  • Table 3.21 Oncology Drugs Approved by the FDA in 2018
  • Table 3.22 Oncology Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2024
  • Table 3.23 Oncology Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
  • Table 3.24 Selected Drugs Which Have Faced Market Access Challenges from NICE, 2013-2015
  • Table 4.1 Pharma Contract Sales Market Segmented by Service Sectors: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
  • Table 4.2 Pharma Contract Sales Market Segmented by Service Sectors: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 4.3 Contract Detailing Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
  • Table 4.4 Contract Detailing Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 4.5 Contract Non-Personal Promotion Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
  • Table 4.6 Contract Non-Personal Promotion Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2024-2029
  • Table 4.7 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
  • Table 4.8 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 4.9 Contract Teledetailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
  • Table 4.10 Contract Teledetailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 4.11 Contract eDetailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
  • Table 4.12 Contract eDetailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 4.13 Medical Education Services Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
  • Table 4.14 Medical Education Services Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 4.15 Sample Management Services Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
  • Table 4.16 Sample Management Services Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 5.1 Leading Regional Pharma Contract Sales Markets: Forecast Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2018-2024
  • Table 5.2 Leading Regional Pharma Contract Sales Markets: Forecast Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2024-2029
  • Table 5.3 US Contract Sales Market: Revenue ($bn), CAGR (%),1995 and 2018
  • Table 5.4 US Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2018-2024
  • Table 5.5 US Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 5.6 US Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
  • Table 5.7 US Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
  • Table 5.8 EU5 Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2018-2024
  • Table 5.9 EU5 Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 5.10 EU5 Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
  • Table 5.11 EU5 Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
  • Table 5.12 UK Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2018-2024
  • Table 5.13 UK Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
  • Table 5.14 German Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 5.15 German Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 5.16 French Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 5.17 French Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 5.18 Italian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 5.19 Italian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 5.20 Spanish Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 5.21 Spanish Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 5.22 Japanese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 5.23 Japanese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 5.24 Japan Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
  • Table 5.25 Japan Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
  • Table 6.1 BRIC Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 6.2 BRIC Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 6.3 BRIC Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
  • Table 6.4 BRIC Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
  • Table 6.5 Chinese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 6.6 Chinese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 6.7 Indian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 6.8 Indian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 6.9 Brazilian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 6.10 Brazilian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 6.11 Russian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
  • Table 6.12 Russian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
  • Table 7.1 Pharma Contract Sales Market: Strengths and Weaknesses 2018-2029
  • Table 7.2 Pharma Contract Sales Market: Opportunities and Threats 2018-2029
  • Table 7.3 Top 10 US Patent Expiries, 2015
  • Table 7.4 Notable US Patent Expiries, 2014
  • Table 7.5 Selected CRM Providers for Pharma Sales, 2016
  • Table 7.6 Orphan Drug Definitions in Leading Regions
  • Table 7.7 Orphan Drug Pipeline by Disease Area, 2013
  • Table 8.1 IQVIA Emerging Market Entries, 2010-2012
  • Table 8.2 IQVIA: Revenues ($bn), AGR (%), CAGR (%), 2014-2018
  • Table 8.3 QuintilesIMS: Financial Performance for Third Quarter Review 2018
  • Table 8.4 UDG Healthcare Group Profile, Business Units and Areas of Expertise, 2016
  • Table 8.5 UDG Healthcare: Revenues ($bn), AGR (%), CAGR (%), 2014-2018
  • Table 8.6 UDG Healthcare divisions, profit and employees
  • Table 8.7 inVentiv Health Commercial Division Subsidiaries, 2016
  • Table 8.8 PDI: Commercial Services Revenues ($bn), AGR (%), CAGR (%), 2010-2014
  • Table 9.1 Pharma Contract Sales Market: Revenues ($bn), CAGR (%) and Market Shares (%) by Sector, 2018, 2024, 2029
  • Table 9.2 Pharma Contract Sales Market: Revenues ($bn), CAGR (%) and Market Shares (%) by Therapeutic Area, 2018, 2024, 2029

List of Figures

  • Figure 2.1 The Services Offered by CSOs that Comprise the Pharma Contract Sales Market, 2018
  • Figure 2.2 Outsourcing Processes in the Pharma Industry, 2018
  • Figure 2.3 Trends Driving the Need for New Sales Models 2018-2029
  • Figure 3.1 Global Pharma Contract Sales Market: Revenues ($bn), 2018-2024
  • Figure 3.2 Global Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 3.3 FDA New Drug Approvals, 2012-2015
  • Figure 3.4 FDA New Drug Approvals, 2014-2018
  • Figure 3.5 Pharma Contract Sales: Market Growth Drivers, 2018-2029
  • Figure 3.6 Pharma Contract Sales Market: Restraints, 2018-2029
  • Figure 3.7 Pharma Contract Sales Market Segmented by Therapeutic Area (Line Graph): Revenue ($bn), 2018-2029
  • Figure 3.8 Pharma Contract Sales Market Segmented by Therapeutic Area (Area Chart): Revenue ($bn), 2018-2029
  • Figure 3.9 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2019
  • Figure 3.10 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2024
  • Figure 3.11 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2029
  • Figure 3.12 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), 2015 and 2030
  • Figure 3.13 Cardiovascular Disease Submarket Forecast: Revenue ($bn), 2018-2029
  • Figure 3.14 Diabetes Prevalence in Leading National Markets, 2014
  • Figure 3.15 Metabolic Disorders Submarket Forecast: Revenue ($bn), 2018-2029
  • Figure 3.16 Oncology Submarket Forecast: Revenue ($bn), 2018-2029
  • Figure 4.1 Pharma Contract Sales Market Segmented by Service Sectors: Revenue ($bn), 2018-2029
  • Figure 4.2 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2018
  • Figure 4.3 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2024
  • Figure 4.4 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2029
  • Figure 4.5 Contract Detailing Submarket Forecast: Revenue ($bn), 2018-2029
  • Figure 4.6 Contract Detailing Submarket: Drivers and Restraints, 2018-2029
  • Figure 4.7 Contract Non-Personal Promotion Submarket Forecast: Revenue ($bn), 2018-2029
  • Figure 4.8 Contract Non-Personal Promotion Submarket Drivers and Restraints, 2018-2029
  • Figure 4.9 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Forecast: Revenues ($bn), 2018-2029
  • Figure 4.10 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Market Shares (%), 2018
  • Figure 4.11 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Market Shares (%), 2029
  • Figure 4.12 Contract Teledetailing Submarket Forecast: Revenues ($bn), 2018-2029
  • Figure 4.13 Contract Teledetailing Submarket: Drivers and Restraints, 2018-2029
  • Figure 4.14 Contract eDetailing Submarket Forecast: Revenues ($bn), 2018-2029
  • Figure 4.15 Contract eDetailing Submarket Drivers and Restraints, 2018-2029
  • Figure 4.16 Medical Education Services Submarket Forecast: Revenues ($bn), 2018-2029
  • Figure 4.17 Medical Education Services Submarket: Drivers and Restraints, 2018-2029
  • Figure 4.18 Sample Management Services Submarket Forecast: Revenues ($bn), 2018-2029
  • Figure 4.19 Sample Management Services Submarket Drivers and Restraints, 2018-2029
  • Figure 5.1 Leading Regional Pharma Contract Sales Markets: Forecast Revenue ($bn), 2018-2029
  • Figure 5.2 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2018
  • Figure 5.3 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2024
  • Figure 5.4 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2029
  • Figure 5.5 US Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 5.6 EU5 Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 5.7 Composition of the EU5 Pharma Contract Sales Market, 2018
  • Figure 5.8 Composition of the EU5 Pharma Contract Sales Market, 2029
  • Figure 5.9 UK Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 5.10 German Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 5.11 French Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 5.12 Italian Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 5.13 Spanish Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 5.14 Japanese Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 6.1 BRIC Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 6.2 BRIC Pharma Contract Sales Market Composition: Revenue ($bn), 2018
  • Figure 6.3 Chinese Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 6.4 Indian Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 6.5 Brazilian Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 6.6 Russian Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
  • Figure 7.1 Orphan Drug Pipeline by Disease Area, 2018
  • Figure 8.1 IQVIA Integrated Health Services Segment: Revenues ($bn), 2014-2018
  • Figure 8.2 QuintilesIMS Total Revenues ($bn), 2016-2018
  • Figure 8.3 UDG Healthcare: Revenues ($bn), 2014-2018
  • Figure 8.4 UDG Healthcare: Ashfield, Sharp and Aquilant Revenues ($bn), 2014-2018
  • Figure 8.5 PDI: Commercial Services Revenues ($bn), 2010-2014
  • Figure 9.1 Pharma Contract Sales Market: Revenues ($bn) by Sector, 2018, 2024, 2029
  • Figure 9.2 Pharma Contract Sales Market: Revenues ($bn), by Therapeutic Area, 2018, 2024, 2029

Companies Listed

  • AbbVie
  • Actavis
  • Actelion Pharmaceuticals
  • Addison Whitney
  • Adheris Health
  • Akrikhin
  • Alexion
  • Allergan PLC
  • Amgen Inc.
  • Andrx Pharmaceutials, Inc.
  • Apple
  • Aralez Pharmaceuticals
  • Arbor Pharms Ireland
  • Arena Pharmaceuticals
  • Argon Global Healthcare Network
  • ARIAD
  • Arista
  • Ashfield Healthcare
  • Ashfield Healthcare Communications
  • AstraZeneca
  • BASF Schweiz AG
  • Bayer Healthcare
  • Berkshire Sterile Manufacturing (BSM)
  • Biogaran
  • Blue Earth Diagnostics, Ltd
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Brusilow Enterprises LLC
  • Campbell Alliance
  • Cegedim
  • Celesio
  • Celgene
  • Clovis Oncology, Inc.
  • CMIC Ashfield
  • Create NYC
  • Daiichi Sankyo
  • Dendreon
  • Depomed
  • Eisai
  • Eli Lilly
  • Encore Health Resources
  • Endo Pharmaceuticals
  • Expansis
  • Galliard
  • Genentech
  • GlaxoSmithKline
  • Grey Healthcare Group
  • Group DCA
  • GSW
  • Haymarket Media
  • Health Kare Pharma International
  • In2Focus
  • INC Research
  • Ingelheim
  • inVentiv Health
  • inVentiv Health Public Relations Group
  • inVentiv Health Selling Solutions
  • inVentiv Medical Communications
  • inVentiv Recruitment Solutions
  • inVentiv Therapeutics Institute
  • Invida
  • IQVIA
  • J&J
  • J. Knipper & Company Inc.
  • Janssen Biotech
  • Kadrige
  • Knowledge Point360
  • Kos Pharmaceuticals
  • Marvecs
  • Medical Communications Group (MCG)
  • MediMedia Health
  • Menarini
  • Merck & Co.
  • Merrimack
  • Microsoft
  • Millennium Pharmaceuticals
  • Mylan N.V
  • Navicor
  • Neurocrine Biosciences
  • NovaMed Pharmaceuticals
  • Novartis
  • Novella Clinical
  • Novo Nordisk A/S
  • OnCall
  • Oracle
  • Otsuka/Bristol-Myers Squibb
  • PALIO
  • Parexel International
  • PDI
  • Pegasus
  • Pfizer
  • Pharmagistics
  • Pharmexx
  • Polpharma
  • Promius Pharma
  • Publicis Healthcare Communications Group (PHCG)
  • Publicis Selling Solutions
  • Publicis Touchpoint Solutions
  • Qforma
  • Quantia
  • Quintiles
  • Ramco Import Export
  • Regulus Therapeutics Inc.
  • Roche
  • Salesforce.com
  • Sanofi
  • Sanofi Aventis
  • Schering-Plough
  • Scientific Voice
  • Sermo
  • Servier
  • Sinclair IS Pharma
  • SmartAnalyst
  • Smithkline Beecham
  • Sofip (Société de Franchise pour l'Information Pharmaceutique)
  • StayinFront
  • Symplmed Pharmaceuticals
  • Syneos Health
  • Synopia Rx
  • Taiho Oncology
  • Takeda
  • Tardis Medical
  • Temas
  • Tesaro
  • Teva Pharmaceutical Industries
  • The Medicines Company
  • United Therapeutics
  • Veeva
  • Vivus
  • Zuellig Group
  • Zuellig Pharma

List of Organizations Mentioned in the Report

  • Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Brazilian Ministério da Saúde
  • Centers of Medicare and Medicaid Services (CMS)
  • European Commission
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Promotional Product Association (EPPA)
  • Gesamtverband der Werbeartikel Wirtschaft e.V. (GWW)
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG)
  • L'Agenzia Italiana del Farmaco (AIFA)
  • Medical Council of India (MCI)
  • National Institute for Health and Care Excellence (NICE)
  • Organization of Pharmaceutical Producers of India (OPPI)
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
Back to Top